In Australia where I live, on 1 December 2017 radical and sweeping changes are about to be made to the National Cervical Screening Program (NCSP) that will impact women’s health significantly. I should note, although I focus on the changes made being made to the NCSP in Australia, other countries have considered or have introduced similar programs. These programs affect how and when cervical cancer screenings take place and, more importantly, whether and which types of cancer will be detected.
Cervical Cancer Screening in Australia
Introduced in 1991, the current NCSP offers routine biennial Pap smear screening for all women aged 18-69 years. Commencement age is 18 years, or two years after beginning sexual activity (or ‘sexual debut’, as it is quaintly termed), whichever is the later. The program has had great success. As a result of its introduction, both the incidence and mortality of cervical cancer has halved to one of the lowest in the world.
“Cervical cancer incidence for women of all ages remains at an historical low of 7 new cases per 100,000 women, and deaths are also low, historically and by international standards, at 2 deaths per 100,000 women.” Source: Australian Institute of Health and Welfare
Now this is all under threat and the NCSP as we know it is about to be decimated. Rather than focus on cervical cancer detection, and thus, prevention, with biennial Pap smears, the new program will rely primarily on HPV vaccination and triage HPV testing. The Renewed NCSP will offer a “cervical screening test” to women only at 5-yearly intervals, and only beginning at age 25 years.
Moreover, this “cervical screening test” will not be the Pap smear. Women will only have a Pap smear if they test positive to HPV. Not only is HPV testing being introduced for the first time as a public health screening strategy; it is being fast-tracked to become the PRIMARY screening tool. This means a Pap smear will only be subsidized by the Government under the Medical Benefits Schedule (MBS) if you first test positive to HPV.
This is a huge and, I would suggest, risky change to the cervical cancer screening program. The Renewed NSCP is based on predictive statistical and economic modelling around the HPV vaccine and triage HPV testing.
There is little regard for the empirical evidence and lessons learned from the 70+ years since the Pap smear test was developed; the 50+ years of organized cervical screening in Australia; and the 26 years of empirical evidence and reporting from the world-acclaimed NCSP. All this accumulated evidence and wisdom is seemingly being ignored, and this worries me. As a DES daughter I believe it is crucial that we remember and learn from past experiences.
Understanding the Reproductive Tract and Cancer
The aim of population cervical cancer screening programs directed specifically at asymptomatic women is to reduce the incidence of invasive cervical cancer. In order to understand why relying on the HPV vaccine and triage HPV testing to prevent incipient cervical cancer is problematic, it is important to understand the types of cervical cancer. Bear with me, this information is a bit technical and complicated, but it is critically important for women to understand the differences to enable educated choices about reproductive health.
Two Types of Cervical Cancer
Cervical cancer affects the cells of the uterine cervix, which is the lower part (or ‘neck’) of the uterus where it joins the inner end of the vagina. It is where the Mullerian-derived glandular tissue from the upper genital tract meets the squamous tissue of the lower or outer genital tract.
Anatomy of the Cervix and Nearby Organs
Cancers of the upper genital tract (e.g. of the ovaries, Fallopian tubes and endometrium) are glandular cell cancers. Cancer of the cervix can be either squamous or glandular.
The Cells of the Cervix
There are two types of cervical cells – squamous and glandular. The Pap smear takes sample cells from the transformation zone of the cervix where the squamous cells and glandular cells meet. This is where most cervical abnormalities and cancer are detected as the cells are undergoing constant change. The sample cells are then examined under a microscope for any abnormal (dysplastic) change. Any abnormalities (both squamous and glandular) are then classified and graded by the cytologist.
Squamous Cell Abnormalities and Cancer
Any abnormal changes to cervical squamous cells typically have a long lead time before cancer, with several preliminary stages before invasive cancer. It is not an inevitable linear progression, as the vast majority of low-grade squamous abnormalities resolve without treatment. Even many high grade abnormalities may regress; if not, they can be treated by a range of procedures.
The terminology has changed over the years, but all the following terms refer to squamous-cell abnormalities: mild, moderate and severe dysplasia; squamous carcinoma in situ (SCIS); HPV effect, HPV wart effect; cervical intraepithelial neoplasia (CIN); CIN1, CIN2, CIN3; squamous intraepithelial lesion (SIL); LSIL and HSIL.
It is critically important to realize that HPV infection relates ONLY to squamous cell abnormalities.
“The papilloma viruses are attracted to and are able to live only in certain cells called squamous epithelial cells. These cells are found on the surface of the skin and on moist surfaces (called mucosal surfaces).”
Source: American Cancer Society
Glandular Cell Abnormalities and Cancer
Like the glandular cancers of the upper genital tract, cervical glandular cancer is more aggressive and has a shorter lead time. There are two precursors to (invasive) adenocarcinoma: atypical glandular cells and adenocarcinoma in situ (AIS). In practice there is no ‘low grade’ glandular-cell abnormality, as any atypical change is referred for immediate colposcopic investigation. Cervical adenocarcinoma is a relatively new phenomenon, with AIS being first described in 1953.
The Success of the Pap Smear and Cervical Screening Programs
The Pap Smear
The Pap smear is named after Dr. George Papanicolaou who developed the test in 1943 . A sample of cells is collected from the transformation zone of the cervix. With the conventional Pap smear, the cells are smeared onto a glass slide, stained and examined under a microscope for any abnormalities. Liquid Based Cytology (LBC) is a newer technology that involves a different method of preparing cervical samples for examination. The cells are placed in a vial containing preservative liquid. The sample is then sent to the laboratory for processing to remove obscuring material before being placed on a slide.
Any cell abnormalities (both squamous and glandular) detected on cytology are then classified and graded, as discussed above. Hence, the Pap smear detects the early precursors of both types of cervical cancer.
The Pap smear became widely accepted as a very effective screening test for cervical cancer: In countries that had programs, morbidity and mortality from invasive squamous cell cancer was considerably reduced.
It can be seen in the following diagram that in Australia the incidence of squamous-cell cancer was more than halved between the years 1982-2002.
Of the cervical cancers diagnosed in 2012, 69.3% were squamous cell cancer. Figure 4.3 shows that for the last 15 years, the relative incidence between squamous and glandular cancer has remained more or less constant at around 70% and 30%, respectively.
The empirical data from the NCSP shows consistently that the biggest risk factor for cervical cancer is not having regular biennial Pap smears. Of Victorian women diagnosed with cervical cancer, 40% had never been screened, and a further 35% were “lapsed screeners” (that is, they hadn’t had a Pap test in the 2.5 years prior to their cancer diagnosis).
Whereas routine Pap screening programs dramatically reduced invasive squamous cancer in Western nations; without proper infrastructure and resources, the rates of cervical cancer in developing nations remain high. That the global burden of cervical cancer is greatest in developing countries is shown in Figure 1, Cervical Cancer: A Preventable Death.
HPV and HPV Testing
HPVs are a group of more than 150 related viruses. Each HPV virus in the group is given a number, which is called an HPV type or strain. The papillomavirus viruses are attracted to and are able to live only in certain cells called squamous epithelial cells. These cells are found on the surface of the skin, and on moist surfaces (called mucosal surfaces). Of the more than 150 known strains, about 75% HPV types are called cutaneous because they cause warts on the skin. The other 25% of the HPV types are mucosal types of HPV, and genital HPV types are in this group.
Source: American Cancer Society
Genital HPV is a very common sexually transmitted infection (STI). It is spread mainly through intimate direct skin-to-skin contact. It’s not spread in blood or other bodily fluids. Genital HPVs are classified as “low risk”: HPV types that tend to cause warts not cancer; or “high risk”: oncogenic HPV types that have the potential to cause cancer.
Like any virus, genital HPV continually evolves and mutates. In Australia of the 40 known genital HPV strains, 15 are considered oncogenic, with HPV types 16, 18 and 45 being the most prevalent.
Infection with one or more of the 40 HPV types is very common. HPV is such a prevalent STI that it could be considered a normal part of being sexually active. Most people will have HPV at some time in their lives and never know it. It is asymptomatic. You may only become aware of HPV is you have an abnormal Pap smear result or if genital warts appear.
Although HPV infection is very common, in most people it clears up naturally in about 8-14 months. In a small number of women, the HPV stays in the cells of the cervix. When the infection is persistent, not cleared readily, there is an increased risk of developing squamous CIN abnormalities.
The HPV Test
In contrast to the Pap smear, the HPV test is not a test for cancer. Cells are collected from the cervix as with a Pap smear but then in the laboratory undergo HPV genotyping to see if one or more oncogenic HPV types are present.
The proposed primary triage HPV test in the Renewed NCSP involves partial HPV genotyping. According to the Medical Services Advisory Committee (MSAC), the authority overseeing the Renewed NCSP, the HPV test must have HPV genotyping capacity to identify HPV 16, 18, and possibly 45.
HPV and Primary Cause Theory
In countries that don’t have Pap smear screening programs, the burden of invasive squamous cancer is great. The precursor CIN abnormalities cannot be detected and hence can progress to invasive cancer. HPV testing provided the tool to look at HPV genotype distribution in invasive and pre-invasive cancer in developing countries. Significant geographic differences in HPV type prevalence were found in different regions worldwide.
During the 1990s hundreds of studies, both large and very small, were undertaken in countries that didn’t have Pap smear screening programs. Meta-analysis of these studies led to the premise that HPV is the primary cause of squamous cancer: Infection with a persistent oncogenic HPV type is the necessary first step before any precursor CINs can develop. This premise that HPV is the primary cause of squamous cell cancer is shown diagrammatically in Figure 1 Natural history of HPV infection and cervical cancer on page 13 of the Medical Services Advisory Committee (2014) MSAC Outcomes – Application No. 1276 report.
In developing countries without Pap smear screening programs, a primary triage HPV testing strategy makes sense.
“In populations where cytology programmes are either not in place or are not efficient, HPV testing should now be considered and evaluated as an alternative test for primary screening.” Source: Bosch et al (2002)
Women who test positive to oncogenic HPV types can then be prioritised to access the limited health care resources available.
This strategy does not make sense, however, in countries with routine Pap smear and gynecological care; and where 30% of the cervical cancers diagnosed are glandular-cell cancers.
If HPV Tests Do Not Detect Cancer, Why Are We Replacing the Pap Smear?
This is a very good question.
An even better question is: Why would you have a Pap smear and not find out the result?
As of 1 December, Australian women will be offered a “cervical screening test”. They will have a LBC Pap smear, where the cervical cells are placed in a vial containing preservative liquid. Instead of being sent to a cytology lab to be screened for cell abnormalities, the vial will be hijacked to a lab for partial HPV genotyping. If it tests positive to HPV 16, 18, or (possibly) 45, the same specimen of cells will then be reanalysed using reflex cytology to see if any squamous or glandular cell abnormalities are present.
How bizarre is that? How very Kafkaesque.
Let’s take a deep breath and heed some wisdom from the recent past. According to the NCSP webpage (2009):
Should I have a special test for HPV?
There is an HPV test available which can identify strains of HPV. This is not a test for cancer…
Because most HPV infections usually resolve naturally, and there is not cure, there is little reason to have an HPV test…
While a Pap smear cannot identify which type of HPV is present, regular Pap smear will make sure any changes that occur are identified early and managed effectively.
The Bottom Line on Pap Smears Versus HPV Testing
The Pap smear is a screening tool that detects CIN abnormalities and adenocarcinoma in situ (AIS), the precursor to adenocarcinoma.
While HPV is the primary cause of squamous cancer; evidence from the NCSP consistently and conclusively shows that the biggest risk factor for cervical cancer is not having regular biennial Pap smears.
Bottom line, the Pap smear detects abnormal cervical cells, both squamous and glandular, and is a long established, very successful screening test for cervical cancer. The HPV test screens for a STI. As a woman, I would argue for a regular Pap smear.
We Need Your Help
Hormones Matter needs funding now. Our research funding was cut recently and because of our commitment to independent health research and journalism unbiased by commercial interests we allow minimal advertising on the site. That means all funding must come from you, our readers. Don’t let Hormones Matter die.